Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.37 |
| ▸ | PPARA | Q07869 | 17/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013188 | 0.85 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL6206380 | 0.78 | PPARA (0.42) | PPARGPPARA | |
| SCHEMBL4013902 | 0.77 | PPARA (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4010340 | 0.71 | PPARA (0.65) | PPARGPPARAPPARD | |
| SCHEMBL4013379 | 0.69 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL4012839 | 0.69 | PPARA (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4017608 | 0.67 | PPARA (0.55) | PPARGPPARAPPARD | |
| SCHEMBL9308272 | 0.65 | EDNRB (0.58) | — | |
| SCHEMBL13924129 | 0.63 | PPARG (0.77) | PPARGPPARA | |
| SCHEMBL4016459 | 0.63 | PPARG (0.77) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366012-A4 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002064094-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |